Civica Welcomes Dr. Dave Sehgal as Chief Manufacturing and Supply Chain Officer
Civica Welcomes Dr. Dave Sehgal as Chief Manufacturing Officer and Supply Chain Officer
Civica, a nonprofit dedicated to addressing drug shortages, has announced the appointment of Dr. Dave Sehgal as its Chief Manufacturing Officer and Supply Chain Officer, effective July 21, 2025. This critical role is expected to enhance Civica's operational strategies as they strive to meet the ever-growing demand for essential medicines. Dr. Sehgal brings with him nearly three decades of experience in the pharmaceutical sector, particularly in manufacturing and supply chain management.
In his new position, Dr. Sehgal will be directly reporting to Civica's President and CEO, Ned McCoy. McCoy expressed excitement about Sehgal's addition to the leadership team, emphasizing the importance of his extensive background in pharmaceutical manufacturing. The expertise he brings is expected to be pivotal as Civica works to operationalize its new facility located in Petersburg, Virginia.
Dr. Sehgal is no stranger to the industry. Most recently, he served as the Vice President and Global Processing Engineering Head at CSL-Behring in Holly Springs, North Carolina. During his tenure there, he managed a team of over 500 scientists and engineers, overseeing global projects aligned with all of CSL-Behring's products. His illustrious career also includes leadership roles at reputable organizations like FUJIFILM Diosynth Biotechnologies, Seqirus, Novartis, and Merck. Dr. Sehgal holds a bachelor’s, master’s, and a doctoral degree in chemical engineering from North Carolina State University.
Commenting on his appointment, Dr. Sehgal expressed his enthusiasm for joining Civica at such a critical juncture in its mission to deliver accessible healthcare solutions. “I am excited to join Civica at this time in the company's history,” he said. “I look forward to leading the team that will bring high-quality, essential generic medicines, manufactured in the United States, to patients who need them.”
The Petersburg facility, which is a modern 140,000 square-foot space and has already begun staff recruitment, currently employs more than 200 skilled workers. Plans are in place to expand the workforce by hiring an additional 60 employees by the end of 2025. This facility is a significant investment for Civica, designed to manufacture vast quantities of essential medicines, with an annual capacity reaching 90 million vials, 50 million syringes, and 120 million pre-filled pens of sterile generic injectable medicines. The site is nearing the end stages of regulatory certification and is expected to commence production in 2026.
This leadership change signifies Civica's ongoing commitment to operational excellence in the pharmaceutical landscape. Civica aims to tackle drug shortages by providing a stable and affordable supply of essential medicines, benefiting both patients and healthcare systems across the United States. Since its inception, Civica has grown out of a collaborative effort by various U.S. health systems and philanthropic organizations that recognized the dire need for a different approach to managing drug supplies.
As Civica continues to expand its footprint in the pharmaceutical sector, Dr. Sehgal's leadership will play a vital role in realizing the organization's goals and fulfilling its mission of ensuring that quality drugs are accessible to all. His appointment is widely viewed as a strategic move towards bolstering Civica's capabilities in delivering essential medications to healthcare providers nationwide.
In summary, the hiring of Dr. Dave Sehgal marks a new chapter for Civica, setting the stage for robust growth and enhanced operational capacities in the competitive landscape of pharmaceutical manufacturing.